AMEVIVE is a CD2-directed LFA-3/Fc fusion protein indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis

-----------------------DOSAGE AND ADMINISTRATION---------------------- 15 mg given once weekly as an intramuscular injection for 12 weeks (2).  AMEVIVE should not be initiated if CD4+ lymphocytes are below normal. Monitor CD4+ T lymphocyte counts every two weeks during the dosing period. If CD4+ T lymphocyte counts are below 250 cells/μL, withhold dosing and institute weekly monitoring. Discontinue AMEVIVE® if CD4+ T lymphocyte counts remain below 250 cells/μL for one month (2).  An additional 12-week course may be initiated if at least 12-weeks have passed since the previous treatment course and the CD4+ T lymphocyte counts are normal (2).